OBJECTIVE： To provide reference for rational use of anti-tumor essential medicine in the clinic. METHODS： The application of anti-tumor essential medicine in 39 hospitals from Chongqing area during 2012-2014 was analyzed statistically in respects of consumption sum， DDDs， DDC and B/A. RESULTS： The total consumption sum of anti-tumor essential medicine in 39 hospitals from Chongqing area during 2012-2014 increased from 10 083.65 ten thousand yuan to 15 186.65 ten thousand yuan， with annual increase rate of 22.72％. 3-year total consumption sum was 37 952.45 ten thousand yuan， and the sum of consumption sum of top 10 medicines was 36 742.24 ten thousand yuan， accounting for 96.81％； top 3 medicines were paclitaxel， oxaliplatin and fluorouracil. During 2012-2014， DDDs had changed to certain extent， and the front medicines contained tegafur， paclitaxel and cyclophosphamide， etc； the most increment medicine was paclitaxel （oral）， whose annual growth rate was 59.63％； that of tamoxifen decreased year by year， with annual decrease rate of 5.14％. DDC of paclitaxel， oxaliplatin and etoposide were the higher others. Annual B/A of oxaliplatin， fluorouracil and cytosine arabinoside were all lower than 1.00. CONCLUSIONS： The lonsumption sum and DDDs of anti-tumor essential medicine had increased reasonably in 39 hospitals from Chongqing area during 2012-2014， while their DDC had kept stable. Main medicines used in the clinic are suitable for numerous indications， and are expensive.